NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade
The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NeoGenomics (NEO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2
Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81.
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AI-boosted medical diagnostics firm Tempus AI given 'buy' rating
Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical and other data to provide a new level of medical diagnostics. There are other companies that provide similar molecular diagnostics – Guardant Health, Foundation Medicine, NeoGenomics (NASDAQ:NEO) for three – Tempus differs from most of them by adding layers of additional patient information such as MRI imaging data, patient records, as well as AI techniques such as neural networks, deep learning, and large language models.
